文献速递消化系统肿瘤

SOX方案联合帕博利珠单抗治疗转移性胃癌的疗效与安全性

[Efficacy and safety of SOX regimen combined with Pembrolizumab in the treatment of metastatic gastric cancer].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2026-01-01

该回顾性研究纳入107例转移性胃癌患者,比较SOX化疗联合帕博利珠单抗与单纯SOX化疗的疗效与安全性。联合组客观缓解率、中位无进展生存期及总生存期均显著优于化疗组,PD-L1 CPS≥1患者获益更明显,Ⅲ~Ⅳ级不良反应无显著增加。

要点

  • 联合组ORR 64.7%显著高于化疗组39.3%(P=0.015)。
  • PD-L1 CPS≥1患者联合组ORR达75.9%,优势更显著(P=0.004)。
  • 联合组中位PFS 9.3个月、OS 17.4个月,均显著优于化疗组。

核心结论

  • 在全部入组患者及PD-L1 CPS≥1患者中,SOX联合帕博利珠单抗较单纯SOX化疗显著提升ORR、延长PFS和OS并改善生活质量,且Ⅲ~Ⅳ级不良反应未见明显增加。

研究设计与样本

  • 回顾性收集2020年5月至2024年5月上海交通大学医学院附属瑞金医院无锡分院收治的107例晚期转移性胃癌患者临床资料。
  • 按治疗方法分为化疗组56例(仅SOX方案化疗)和联合组51例(SOX方案联合帕博利珠单抗)。

主要发现

  • 全部受试者中联合组ORR为64.7%,显著高于化疗组的39.3%(P=0.015)。
  • PD-L1 CPS≥1患者中联合组ORR为75.9%(22/29),化疗组为38.9%(14/36),差异有统计学意义(P=0.004)。
  • 全部入组患者中联合组中位PFS 9.3个月、中位OS 17.4个月,化疗组分别为8.4个月和13.1个月(PFS P=0.020,OS P=0.011)。
  • PD-L1 CPS≥1患者中联合组中位PFS 10.7个月、中位OS 19.0个月,化疗组分别为8.2个月和12.8个月(PFS P=0.003,OS P=0.005)。
  • 联合组生活质量改善率为45.1%(23/51),显著高于化疗组的25.0%(14/56)(P=0.029)。

关键数值与推荐

  • 疗效评价采用RECIST1.1标准:化疗组CR 1例、PR 21例;联合组CR 2例、PR 31例。
  • Ⅲ~Ⅳ级不良反应发生率化疗组67.9%(38/56),联合组78.4%(40/51),差异无统计学意义(P=0.219)。

临床怎么用

  • 对于转移性胃癌患者,尤其是PD-L1 CPS≥1者,可考虑SOX方案联合帕博利珠单抗以提升缓解率并延长生存。
  • 联合方案未显著增加Ⅲ~Ⅳ级不良反应,但需关注联合组不良反应发生率数值上偏高的趋势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the clinical efficacy, toxicity and prognosis of SOX regimen (Oxaliplatin plus S-1) combined with Pabolizumab in the treatment of patients with metastatic gastric cancer. Methods: The clinical data of 107 patients with advanced metastatic gastric cancer admitted to Wuxi Branch of Ruijin Hospital Shanghai Jiao Tong University School of Medicine from May 2020 to May 2024 were retrospectively collected. According to the treatment methods, the patients in the chemotherapy group (n=56) only received SOX chemotherapy, and the patients in the combined group (n=51) were given SOX chemotherapy combined with Pembrolizumab. The differences of objective response rate (ORR), median progression-free survival (PFS), median overall survival (OS), grade Ⅲ-Ⅳ toxicity and quality of life improvement rate between the two groups were analyzed and compared. Results: According to the efficacy evaluation criteria of RECIST1.1, among all subjects, there were 1 case of complete response (CR) and 21 cases of partial response (PR) in chemotherapy group, 2 cases of CR and 31 cases of PR in combination group. The objective response rate (CR+PR%) in combination group was significantly higher than that in chemotherapy group (64.7% vs 39.3%, P=0.015). Stratified analysis showed that in patients with PD-L1 combined positive score (CPS) ≥1, the ORR of the combination group further increased to 75.9% (22/29), with a more significant advantage than the ORR of 38.9% (14/36) in the chemotherapy group (P=0.004). Survival analysis showed that among all enrolled patients, median PFS and median OS in combination group were 9.3 months and 17.4 months respectively, which were significantly longer than 8.4 and 13.1 months in chemotherapy group (PFS: P=0.020; OS: P=0.011). In addition, among patients with PD-L1 CPS ≥1, the median PFS and OS of the combination group showed a more significant advantage in prolonging compared to the chemotherapy group (median PFS: 10.7 months vs 8.2 months, P=0.003; median OS: 19.0 months vs 12.8 months, P=0.005). Among all enrolled patients, 14 cases showed improvement in quality of life in the chemotherapy group and 23 cases in the combination group, and the improvement rate of quality of life in combination group was significantly higher than that in chemotherapy group (45.1% vs 25.0%, P=0.029). There was no statistical difference in the incidence [67.9% (38/56) in chemotherapy group vs 78.4% (40/51) in combination group] of grade Ⅲ-Ⅳ toxicity between the two groups (P=0.219). Conclusion: In patients with PD-L1 CPS ≥1 or all enrolled patients, compared with chemotherapy alone, SOX regimen combined with pembrolizumab in the treatment of metastatic gastric cancer can significantly improve ORR, prolong PFS and OS, improve prognosis and quality of life, while the toxicity has not increased significantly. 目的: 探讨SOX方案(奥沙利铂+替吉奥)联合帕博利珠单抗治疗转移性胃癌患者的临床疗效、不良反应及预后。 方法: 回顾性收集上海交通大学医学院附属瑞金医院无锡分院2020年5月至2024年5月收治的107例晚期转移性胃癌患者的临床资料,根据治疗方法分为化疗组(n=56)和联合组(n=51),化疗组患者仅接受SOX方案化疗,联合组患者给予SOX方案联合帕博利珠单抗治疗。比较客观缓解率(ORR)、中位无进展生存时间(PFS)、中位总生存时间(OS)、Ⅲ~Ⅳ级不良反应、生活质量改善率等观察指标在两组间的差异。 结果: 根据实体瘤的疗效评价标准1.1版评估疗效,在全部受试者中,化疗组有1例完全缓解(CR)、21例部分缓解(PR),联合组有2例CR、31例PR,联合组ORR(CR+PR)显著高于化疗组(64.7%和39.3%,P=0.015)。分层分析显示,在程序性死亡受体配体1(PD-L1)联合阳性评分(CPS)≥1分的患者中,联合组ORR进一步提升至75.9%(22/29),较化疗组ORR 38.9%(14/36)升高优势更为明显(P=0.004)。生存分析显示,在全部入组患者中,化疗组中位PFS、中位OS分别为8.4和13.1个月,而联合组中位PFS、中位OS分别为9.3和17.4个月,均较化疗组明显延长(PFS P=0.020,OS P=0.011);此外,在PD-L1 CPS≥1分的患者中,联合组的中位PFS及OS对比化疗组的延长优势均更加显著(中位PFS:10.7和8.2个月,P=0.003;中位OS:19.0和12.8个月,P=0.005)。所有入组患者中化疗组生活质量改善者14例,联合组为23例,联合组生活质量改善率较化疗组显著升高[45.1%(23/51)和25.0%(14/56),P=0.029]。化疗组和联合组间Ⅲ~Ⅳ级不良反应发生率[化疗组67.9%(38/56),联合组78.4%(40/51)]差异无统计学意义(P=0.219)。 结论: 在PD-L1 CPS≥1分的患者或所有入组胃癌患者中,与单纯化疗相比,SOX方案联合帕博利珠单抗治疗转移性胃癌可显著提升ORR,并延长PFS、OS,改善预后,提高生活质量,而不良反应未见明显增加。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhao W, Yan J, Luo Y, et al. [Efficacy and safety of SOX regimen combined with Pembrolizumab in the treatment of metastatic gastric cancer]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 42086524. doi:10.3760/cma.j.cn112152-20250608-00264

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。